Phaseline

Targets › GBA

GBA (Lysosomal acid glucosylceramidase): drug programs, companies and trials

8 programs from 8 companies in 15 trials: 6 Phase 1, 5 Phase 3, 4 Phase 2; Neurology, Metabolic and endocrine, Hematology; next expected readout Feb 2027.

Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) into free ceramides (such as N-acylsphing-4-enine) and glucose. Plays a central role in the degradation of complex lipids and the turnover of cellular membranes. (UniProt, P04062)

Open in Phaseline: the race on GBA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AzafarosNizubaglustat (AZ-3102)
Glucosidase inhibitor
GBA, UGCGPhase 3Gangliosidoses, GM2; Niemann-Pick Type C Disease; GM2 GangliosidosisJun 2027
Spur TherapeuticsFLT201
AAV-mediated gene therapy delivering functional GBA gene
GBAPhase 3Gaucher Disease Type 1; Gaucher Disease, Type 1Jul 2028
University College, LondonAmbroxol Hydrochloride
Glucocerebrosidase activator / lysosomal function enhancer
GBAPhase 3Parkinson DiseaseFeb 2029
Chinese PLA General HospitalEliglustat
Glucosylceramide synthase (GSL synthetase) inhibitor
GBAPhase 2Colorectal Cancer; LymphomaMar 2027
Helse FonnaAmbroxol
Glucocerebrosidase (GCase) enhancing chaperone
GBAPhase 2Dementia With Lewy BodiesSep 2027
Bial R&D InvestmentsBIA 28-6156
Glucocerebrosidase activator
GBAPhase 2Parkinson's Disease–
Prevail TherapeuticsLY3884961
Recombinant adeno-associated virus (AAV) vector delivering GBA gene
GBAPhase 1Gaucher Disease, Type 2; Gaucher Disease; Parkinson DiseaseFeb 2027
Lingyi BiotechLY-M001 Injection
rAAV8 vector gene therapy expressing glucocerebrosidase (GCase)
GBAPhase 1Gaucher Disease Type 1Jul 2027

Conditions

Parkinson Disease (2) Gaucher Disease Type 1 (2) Niemann-Pick Type C Disease (2) Colorectal Cancer (1) Lymphoma (1) Gaucher Disease, Type 1 (1) Gaucher Disease, Type 2 (1) Gaucher Disease (1) Gangliosidoses, GM2 (1) GM2 Gangliosidosis (1) Dementia With Lewy Bodies (1) Parkinson's Disease (1)

Modalities

small molecule (5), other (3)

Companies

University College, London (1) Lingyi Biotech (1) Chinese PLA General Hospital (1) Spur Therapeutics (1) Prevail Therapeutics (1) Azafaros (1) Helse Fonna (1) Bial R&D Investments (1)

Related targets

UGCG (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.